Kelly Schick Net Worth

The estimated Net Worth of Kelly Schick is at least $684 Mille dollars as of 30 August 2023. Ms. Schick owns over 2,250 units of AMAG Pharmaceuticals stock worth over $683,675 and over the last 5 years she sold AMAG stock worth over $0. In addition, she makes $0 as Chief Human Resource Officer e Senior Vice President at AMAG Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Schick AMAG stock SEC Form 4 insiders trading

Kelly has made over 3 trades of the AMAG Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently she exercised 2,250 units of AMAG stock worth $56,250 on 30 August 2023.

The largest trade she's ever made was exercising 3,750 units of AMAG Pharmaceuticals stock on 30 January 2023 worth over $93,750. On average, Kelly trades about 813 units every 39 days since 2020. As of 30 August 2023 she still owns at least 27,347 units of AMAG Pharmaceuticals stock.

You can see the complete history of Ms. Schick stock trades at the bottom of the page.

Kelly Schick biography

Kelly Schick serves as Chief Human Resource Officer, Senior Vice President of the Company. She is our Senior Vice President and Chief Human Resources Officer, joined us as Executive Director, Human Resources in September 2016. Prior to AMAG, Ms. Schick served as head of global talent for Bristol-Myers Squibb (BMS) where she had responsibility for global talent management, talent acquisition, learning and development, organization effectiveness and diversity and inclusion for the company's global manufacturing division from January 2011 to September 2016. Before joining BMS in 2011, Ms. Schick held a series of HR business partner roles of increasing responsibility supporting the research and development organization for Merck and Company, Inc. Ms. Schick holds a Bachelor of Arts in psychology from Boston University and a Master of Arts in human resources and labor relations from the Curtis L. Carlson School of Management at the University of Minnesota.

How old is Kelly Schick?

Kelly Schick is 40, she's been the Chief Human Resource Officer e Senior Vice President of AMAG Pharmaceuticals since 2016. There are 11 older and 1 younger executives at AMAG Pharmaceuticals. The oldest executive at AMAG Pharmaceuticals, Inc. is Davey Scoon, 73, who is the Independent Director.

What's Kelly Schick's mailing address?

Kelly's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN, MA, 02472.

Insiders trading at AMAG Pharmaceuticals

Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C.... e Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.

What does AMAG Pharmaceuticals do?

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Complete history of Ms. Schick stock trades at AMAG Pharmaceuticals e C4 Therapeutics

AMAG Pharmaceuticals executives and stock owners

AMAG Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Vittiglio,
  Executive Vice President, General Counsel, Corporate Secretary, Chief Business Officer
• Anthony Casciano,
  Chief Operating Officer, Executive Vice President and Chief Commercial Officer
• Gino Santini,
  Independent Chairman of the Board
• Kathrine O'Brien,
  Independent Director
• Anne Phillips,
  Independent Director
• Davey Scoon,
  Independent Director
• John Fallon,
  Independent Director
• James Sulat,
  Independent Director
• David Johnson,
  Independent Director
• Paul Fonteyne,
  Independent Director
• Linda Lennox,
  Vice President - Investor Relations and Corporate Communications
• Nancy Griffith,
  Vice President - Scientific Communications And Medical Operations
• Kelly Schick,
  Chief Human Resource Officer, Senior Vice President
• Brian Piekos,
  Chief Financial Officer
• Scott Myers,
  President, Chief Executive Officer, Director
• Barbara Deptula,
  Director
• Brian P Kelley,
  Director
• Lesley Russell,
  Director
• Robert J Perez,
  Director
• Edward H Myles,
  COO & CFO
• William K Heiden,
  President & CEO
• Nicholas Grund,
  Chief Commercial Officer
• Elizabeth Scott Bolgiano,
  Chief Human Resources Officer
• Partners Lp Caligan,
  10% owner
• Julie Krop,
  Chief Medical Officer
• James Alan Butcher,
  EVP, Chief Business Officer
• Capital Management Lp Camber,
  
• Capital, Llc Armistice Capi...,
  
• Kenneth H Wilson,
  SVP, Sales and Marketing
• Geoffrey Crouse,
  EVP
• Edward P. Jordan,
  SVP, Sales and Marketing
• Scott B Townsend,
  SVP, General Counsel
• Capital Partners Gp, L.L.C....,
  
• Steven Caffe,
  SVP, Ch. Dev. and Reg. Officer
• Ron Zwanziger,
  Director
• Michael Narachi,
  Director
• Sheldon L Bloch,
  Director
• Christopher G White,
  Chief Business Officer and SVP
• Jerome M Lewis,
  VP of Scientific Operations
• David Arkowitz,
  CFO & Chief Business Officer
• Jerome Goldstein,
  CEO and Treasurer
• Ricardo Zayas,
  Sr. Vice President, Operations
• Mark B Skaletsky,
  Director
• Silva Rajiv De,
  Director
• Gary J Zieziula,
  EVP, Chief Commercial Officer
• Michael D Loberg,
  Director
• Frank E Thomas,
  President & COO
• Michael N Avallone,
  VP-Finance and CFO
• Scott A Holmes,
  Chief Accounting Officer
• Joseph Vincent Bonventre,
  Director
• Brian Jg Pereira,
  President and CEO
• Greg Madison,
  EVP, Chief Commercial Officer
• Theodore I Steinman,
  Director
• Edward B Roberts,
  Director
• Timothy G Healey,
  SVP-Commercial Operations
• Lee F Md Ph D Allen,
  CMO & SVP Clinical Dev.
• Joseph L Farmer,
  Gen Counsel & VP Legal Affairs
• Louis Md Brenner,
  Senior Vice President